M) in 2023. The essential rationale behind this perspective is to break down our current position on Atossa for private investors considering to short it. We will break down why Atossa Genetics private investors may still consider a stake in the business. " name="Description" /> M) in 2023. The essential rationale behind this perspective is to break down our current position on Atossa for private investors considering to short it. We will break down why Atossa Genetics private investors may still consider a stake in the business. " /> M) in 2023. The essential rationale behind this perspective is to break down our current position on Atossa for private investors considering to short it. We will break down why Atossa Genetics private investors may still consider a stake in the business. " />

Estimating Atossa Genetics (USA Stocks:ATOS) price for March 2023.

Atossa Genetics Asset Turnover is comparatively stable at the moment as compared to the past year. Atossa Genetics reported Asset Turnover of 0.0018 in 2022. Book Value per Share is likely to gain to 1.09 in 2023, whereas Earnings before Tax are likely to drop (20 M) in 2023. The essential rationale behind this perspective is to break down our current position on Atossa for private investors considering to short it. We will break down why Atossa Genetics private investors may still consider a stake in the business.
Published over six months ago
View all stories for Atossa Genetics | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Vlad Skutelnik

The company has a beta of 0.9073. Let's try to break down what Atossa's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Atossa Genetics will likely underperform. The beta indicator helps investors understand whether Atossa Genetics moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Atossa deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Atossa Genetics. Regardless of method or technology, to accurately forecast the stock or bond market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Atossa Genetics

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Atossa Genetics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Atossa Genetics in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Atossa Genetics. Your research has to be compared to or analyzed against Atossa Genetics' peers to derive any actionable benefits. When done correctly, Atossa Genetics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Atossa Genetics.

Watch out for price decline

Please consider monitoring Atossa Genetics on a daily basis if you are holding a position in it. Atossa Genetics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Atossa Genetics stock to be traded above the $1 level to remain listed. If Atossa Genetics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Atossa Genetics's Liquidity

Atossa Genetics financial leverage refers to using borrowed capital as a funding source to finance Atossa Genetics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Atossa Genetics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Atossa Genetics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Atossa Genetics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Atossa Genetics's total debt and its cash.

Atossa Genetics Gross Profit

Atossa Genetics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Atossa Genetics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Atossa Genetics Gross Profit growth over the last 10 years. Please check Atossa Genetics' gross profit and other fundamental indicators for more details.

A Deeper look at Atossa

The newest indifference towards the small price fluctuations of Atossa Genetics could raise concerns from private investors as the firm is trading at a share price of 0.75 on very low momentum in volume. The company directors and management did not add any value to Atossa Genetics investors in January. However, most investors can still diversify their portfolios with Atossa Genetics to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.99. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Atossa Genetics partners.

Returns Breakdown

Return on Assets(0.17)
Return on Equity(0.18)
Return Capital(12.52)
Return on Sales(8,280.75)

Some Atossa technical indicators suggest throwback

Newest Jensen Alpha is up to 0.05. Price may drop again. Atossa Genetics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Atossa Genetics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Atossa Genetics future alpha. Atossa Genetics is a potential penny stock. Although Atossa Genetics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Atossa Genetics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Atossa instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Our Bottom Line On Atossa Genetics

Whereas some other companies within the biotechnology industry are still a little expensive, even after the recent corrections, Atossa Genetics may offer a potential longer-term growth to private investors. On the whole, as of the 26th of February 2023, we believe that at this point, Atossa Genetics is undervalued with close to average probability of bankruptcy within the next 2 years. Our current buy-or-sell advice on the firm is Cautious Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Atossa Genetics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com